BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 17045167)

  • 21. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter.
    Dwyer RM; Bergert ER; O'connor MK; Gendler SJ; Morris JC
    Clin Cancer Res; 2005 Feb; 11(4):1483-9. PubMed ID: 15746050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retinoic acid induces sodium/iodide symporter gene expression and radioiodide uptake in the MCF-7 breast cancer cell line.
    Kogai T; Schultz JJ; Johnson LS; Huang M; Brent GA
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8519-24. PubMed ID: 10890895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiation-induced thyroid stunning: differential effects of (123)I, (131)I, (99m)Tc, and (211)At on iodide transport and NIS mRNA expression in cultured thyroid cells.
    Lundh C; Lindencrona U; Postgård P; Carlsson T; Nilsson M; Forssell-Aronsson E
    J Nucl Med; 2009 Jul; 50(7):1161-7. PubMed ID: 19525464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implications of the molecular characterization of the sodium-iodide symporter (NIS).
    Schmutzler C; Köhrle J
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 3():S1-10. PubMed ID: 9865544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS).
    Fortunati N; Catalano MG; Marano F; Mugoni V; Pugliese M; Bosco O; Mainini F; Boccuzzi G
    Breast Cancer Res Treat; 2010 Dec; 124(3):667-75. PubMed ID: 20213084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas.
    Saito T; Endo T; Kawaguchi A; Ikeda M; Katoh R; Kawaoi A; Muramatsu A; Onaya T
    J Clin Invest; 1998 Apr; 101(7):1296-300. PubMed ID: 9525971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium iodide symporter/radioactive iodine system has more efficient antitumor effect in three-dimensional spheroids.
    Mitrofanova E; Hagan C; Qi J; Seregina T; Link C
    Anticancer Res; 2003; 23(3B):2397-404. PubMed ID: 12894520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter.
    Spitzweg C; O'Connor MK; Bergert ER; Tindall DJ; Young CY; Morris JC
    Cancer Res; 2000 Nov; 60(22):6526-30. PubMed ID: 11103823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
    Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retinoic acid modulation of thyroid dual oxidase activity in rats and its impact on thyroid iodine organification.
    Mühlbauer M; da Silva AC; Marassi MP; Lourenço AL; Ferreira AC; de Carvalho DP
    J Endocrinol; 2010 Jun; 205(3):271-7. PubMed ID: 20212023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mitogen-activated protein kinase signaling enhances sodium iodide symporter function and efficacy of radioiodide therapy in nonthyroidal cancer cells.
    Jung KH; Paik JY; Ko BH; Lee KH
    J Nucl Med; 2008 Dec; 49(12):1966-72. PubMed ID: 18997042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel loss-of-function deletion in sodium/iodide symporter gene in follicular thyroid adenoma.
    Liang JA; Chen CP; Huang SJ; Ho TY; Hsiang CY; Ding HJ; Wu SL
    Cancer Lett; 2005 Dec; 230(1):65-71. PubMed ID: 16253762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy and noninvasive imaging with a dual therapeutic vector expressing MDR1 short hairpin RNA and a sodium iodide symporter.
    Park SY; Kwak W; Thapa N; Jung MY; Nam JO; So IS; Kim SY; Yoo J; Lee J; Kim IS
    J Nucl Med; 2008 Sep; 49(9):1480-8. PubMed ID: 18703598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered gene expression profiles by sodium/iodide symporter gene transfection in a human anaplastic thyroid carcinoma cell line using a radioactive complementary DNA microarray.
    Gol Choe J; Kim YR; Kim KN; Choo HJ; Shin JH; Lee YJ; Chung JK; Kim MK
    Nucl Med Commun; 2005 Dec; 26(12):1155-62. PubMed ID: 16264365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cotransfected sodium iodide symporter and human tyroperoxidase genes following human telomerase reverse transcriptase promoter for targeted radioiodine therapy of malignant glioma cells.
    Li W; Tan J; Wang P; Wu P
    Cancer Biother Radiopharm; 2011 Aug; 26(4):443-51. PubMed ID: 21797672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined RNA interference of hexokinase II and (131)I-sodium iodide symporter gene therapy for anaplastic thyroid carcinoma.
    Kim JE; Ahn BC; Hwang MH; Jeon YH; Jeong SY; Lee SW; Lee J
    J Nucl Med; 2011 Nov; 52(11):1756-63. PubMed ID: 21994409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes.
    Elisei R; Vivaldi A; Agate L; Ciampi R; Molinaro E; Piampiani P; Romei C; Faviana P; Basolo F; Miccoli P; Capodanno A; Collecchi P; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2403-11. PubMed ID: 15623821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishment and characterization of a breast cancer cell line expressing Na+/I- symporters for radioiodide concentrator gene therapy.
    Nakamoto Y; Saga T; Misaki T; Kobayashi H; Sato N; Ishimori T; Kosugi S; Sakahara H; Konishi J
    J Nucl Med; 2000 Nov; 41(11):1898-904. PubMed ID: 11079502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid.
    Wapnir IL; Goris M; Yudd A; Dohan O; Adelman D; Nowels K; Carrasco N
    Clin Cancer Res; 2004 Jul; 10(13):4294-302. PubMed ID: 15240514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma.
    Ma XJ; Huang R; Kuang AR
    Cancer Invest; 2009 Jul; 27(6):673-81. PubMed ID: 19241193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.